Enlivex: A Necessary Update - This Is No Longer The Company We Covered In 2022 [Seeking Alpha]
Enlivex Therapeutics Ltd. - Ordinary Shares (ENLV)
Company Research
Source: Seeking Alpha
on "two distinct pillars": a digital-asset prediction-market strategy and continued clinical development. Its main pillar is a digital-asset treasury strategy built around RAIN — a protocol that allows users to create and trade markets on future events. The "biotech pillar" is now centered on knee osteoarthritis, where Allocetra has delivered encouraging six-month Phase IIa results across pain, function, and safety. ENLV's identity, risk profile, and drivers have fundamentally shifted, demanding a reset of investor expectations and valuation frameworks. Sergey Sidorov/iStock via Getty Images A rather unusual corporate move In 2022, when we last wrote about Enlivex Therapeutics ( ENLV ) on Seeking Alpha, the company was a small Israeli biotech built around macrophage reprogramming, with Allocetra as its flagship program. Our analysis This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of ENLV either through stock ownershi
Show less
Read more
Impact Snapshot
Event Time:
ENLV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENLV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENLV alerts
High impacting Enlivex Therapeutics Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ENLV
News
- Greenberg Traurig Advises Enlivex in $212M Private PlacementPR Web
- Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical DevelopmentGlobeNewswire
- Enlivex Announces Closing of Previously Announced $212,000,000 Private PlacementGlobeNewswire
- Enlivex Therapeutics (NASDAQ:ENLV) was downgraded by analysts at D Boral Capital from a "strong-buy" rating to a "hold" rating.MarketBeat
- Enlivex Therapeutics (NASDAQ:ENLV) had its "hold" rating reaffirmed by analysts at D. Boral Capital.MarketBeat
ENLV
Sec Filings
- 12/4/25 - Form 6-K
- 11/26/25 - Form 6-K
- 11/24/25 - Form 6-K
- ENLV's page on the SEC website